EGFR and familial pancreatic carcinoma: Combinational application of extracted macrophage cell membrane‐coated, gemcitabine‐embedded PLGA NPs and erlotinib (an EGFR inhibitor) in pancreatic cancer models indicated superior targeting of the nanocarriers to the tumor site, plus tumor cells' growth and angiogenesis impediment due to targeting the Ras/Raf/MEK/ERK and PI3K/Akt/ mammalian target of rapamycin (mTOR) signaling pathways, which together emphasizes their efficient therapeutic potency.142